source
- BMS reports phase 3 successes in IPF drug and neuroendocrine tumor radiotherapyBristol Myers Squibb announced that two of its phase 3 trials have met primary endpoints, marking important milestones as the company seeks growth beyond its patent expirations. The Aloft-IPF stud…
- Roche reports updated eye drug data and FDA filing acceptance, targets July 2027 decisionRoche Genentech has presented new data from its eye disease trials, a year after a mixed Phase 3 readout, and noted that the FDA has accepted its filing for vamikibart with a decision slated for Ju…